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Wnt5a is classified as a non-transforming Wnt family member and plays complicated roles in oncogenesis and cancer
metastasis. However, Wnt5a signaling in osteosarcoma progression remains poorly defined. In this study, we found
that Wnt5a stimulated the migration of human osteosarcoma cells (MG-63), with the maximal effect at 100 ng/ml, via
enhancing phosphorylation of phosphatidylinositol-3 kinase (PI3K)/Akt. PI3K and Akt showed visible signs of basal
phosphorylation and elevated phosphorylation at 15 min after stimulation with Wnt5a. Pharmaceutical inhibition of
PI3K with LY294002 significantly blocked the Wnt5a-induced activation of Akt (p-Ser473) and decreased Wnt5a-induced
cell migration. Akt siRNA remarkably inhibited Wnt5a-induced cell migration. Additionally, Wnt5a does not alter the
total expression and phosphorylation of β-catenin in MG-63 cells. Taken together, we demonstrated for the first time
that Wnt5a promoted osteosarcoma cell migration via the PI3K/Akt signaling pathway. These findings could provide a
rationale for designing new therapy targeting osteosarcoma metastasis.
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Osteosarcoma, characterized by a high malignant and
metastatic potential, principally affects children and ado-
lescents [1]. Progression of disease is inexorable and re-
sponse to therapy can be unrewarding: fewer than 50%
of patients live beyond 10 years, and there are no reliable
predictors to guide the choice or intensity of therapy
[1,2]. Several improvements in understanding the mo-
lecular pathology of metastatic osteosarcoma have been
achieved in the last several years [1]. However, the mo-
lecular mechanisms underlying this malignancy are still
largely unknown. For this reason, elucidating the sig-
naling pathways involved in the metastatic cascade has
become a key goal for developing novel effective thera-
peutics aimed at reducing osteosarcoma mortality rates.
Wnt signaling regulates several developmental and
oncogenic processes in both insects and vertebrates [3].
Signals triggered by Wnt are classified into two groups, a
canonical β-catenin pathway and non-canonical pathways.
In the canonical pathway, Wnt signals are mediated by* Correspondence: Ailiangzhang07@163.com
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reproduction in any medium, provided the ordisheveled (Dvl), which inhibits glycogen synthase kinase-
3β (GSK-3β) activity [4]. The accumulated β-catenin
enters the nucleus, forms complexes as a co-factor with
Tcf/Lef transcription factors, and then triggers transcrip-
tion of a set of target genes, which ultimately leads to
regulation of cell proliferation and cell fate as well as cell
transformation [5]. Compared to the canonical pathway,
the non-canonical Wnt pathways are not fully understood,
especially in mammals, while its contributions to cell po-
larity in Drosophila (a planar cell polarity pathway, a PCP
pathway) and convergent extension movement in Xenopus
and zebrafish are demonstrated [6-9]. Wnt5a has been
originally classified into the non-canonical Wnt group and
reported to trigger Ca2+ pathways that subsequently acti-
vate protein kinase C (PKC) and Ca2+/Calmodulin kinase
II [10,11]. Wnt5a can activate other intracellular protein
kinases such as extracellular signal-regulated kinase
(ERK), Akt and c-Jun N-terminal kinase (JNK) [12,13].
It has been reported that trimeric G protein mediated
activation of phospholipase C and phosphodiesterase is
involved in Wnt-induced gene expression [14]. Phos-
phatidylinositol-3 kinases (PI3Ks) are a family of enzymes
involved in cellular functions including cell growth,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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cellular trafficking, all of which can potentially influence
the development of cancer. The serine/threonine kinase
Akt is a major effector of the PI3K pathway and is acti-
vated by many polypeptide growth factors [15]. In this
study, we hypothesized that the PI3K/Akt signaling path-




Human osteosarcoma cell line MG-63 purchased from
Cells Resource Center of Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences (Shanghai, China)
and were cultured in Dulbecco-modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS).
Small interfering RNA (siRNA)
For gene knockdown, siRNA duplexes specific for Akt
(Cell Signaling) were transfected into MG-63 cells by
using Lipofectamine 2000 reagent (Invitrogen, Carlsbad,
CA) in serum-free OPTI-MEM according to the manufac-
turer’s instructions. Knockdown efficiency was evaluated
48 h after transfection by measuring protein levels in cell
lysates through using immunoblotting.
Immunoblotting analysis
Subconfluent cells were washed twice with PBS, and then
lysed with ice-cold RIPA lysis buffer (50 mmol/L Tris,
150 mmol/L NaCl, 1% Triton X-100, 1% sodium deoxy-
cholate, 0.1% SDS, 1 mmol/L sodium orthovanadate,
1 mmol/L sodium fluoride, 1 mmol/L EDTA, 1 mmol/L
PMSF, and 1% cocktail of protease inhibitors) (pH7.4).
The lysates were then clarified by centrifugating at
12,000 g for 20 min at 4°C. The protein extracts were
separated by SDS-PAGE. The immunoblotting procedure
was performed as described [16] and the following anti-
bodies were used: mouse anti-β-actin antibody (KangChen
Bio-tech, Shanghai, China), rabbit anti-Akt antibody,
rabbit anti-phospho-Akt (p-Ser473) antibody, rabbit
anti-PI3K p85 antibody, rabbit anti-phospho-PI3K p85
(Tyr458) (Cell Signaling Technology, Danvers, MA),
mouse anti-β-catenin antibody, rabbit anti-phospho-β-
catenin (p-Ser33) antibody (Santa Cruz Biotechnology,
Santa Cruz, CA). Protein bands were detected by incuba-
ting with horseradish peroxidase-conjugated antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA) and visua-
lized with ECL reagent (Thermo Scientific, Rockford, IL).
Wound healing assay
MG-63 cells were plated onto 96-well cell culture clus-
ters (Costar) and grown to confluence, and then serum-
starved for 24 h. The monolayer cells were scratchedmanually with a plastic pipette tip, and after two washes
with PBS, the wounded cellular monolayer was allowed
to heal for 10 h in DMEM containing 100 ng/ml recom-
binant Wnt5a (rWnt5a) (R&D Systems). Photographs of
central wound edges per condition were taken at time 0
and at the indicated time points using digital camera
(Nikon, Tokyo, Japan).
Cell migration assays
Cell migration was assessed in a modified Boyden cham-
ber (Costar), in which two chambers were separated by a
polycarbonate membrane (pore diameter, 8.0 μm). MG-
63 cells were grown to subconfluence in tissue culture
plates and then detached; thereafter, they were centri-
fuged and rendered into single cell suspensions in
serum-free culture medium supplemented with 5 μg/mL
BSA. The suspensions containing 5 × 104 cells were
added to wells with a membrane placed in the bottom.
Medium containing indicated Wnt5a was added to the
upper and lower compartment of the Boyden chamber.
The cells were allowed to migrate for the indicated pe-
riods of time at 37°C in this assay. Thereafter, the
medium was discarded, stationary cells were removed
with a cotton-tipped applicator and the membranes were
cut out of the chamber and stained with 0.5% crystal
violet. The response was evaluated in a light microscope
by counting the number of cells that had migrated into
the membrane.
Statistical analysis
All experiments here were repeated at least three times,
with independent treatments, each of which showed es-
sentially the same results. The data were analyzed using
Student’s t-test by SPSS statistical software package. All
the results were expressed as mean ± SD. For all analyses
a two-sided p value of less than 0.05 was deemed statisti-
cally significant. This study had been approved by insti-
tutional ethics committee of Changzhou No. 1 People’s
Hospital.
Results
Wnt5a stimulates osteosarcoma cell migration in vitro
To assess the effect of Wnt5a on osteosarcoma cell
migration, we treated MG-63 cells with different doses
of recombinant Wnt5a (rWnt5a), and measured the
migration rate by wound healing assays and Boyden
chamber assays. We found that Wnt5a had a potent
stimulatory effect on MG-63 cell migration (Figure 1A,
1B). An approximately 2-fold increase in cell migration
was observed in cells treated with 100 ng/ml rWnt5a
(Figure 1A, 1B). Nevertheless, low concentration of
Wnt5a (50 ng/ml) has no stimulative effect on MG-63
cell migration (Figure 1A). Accordingly, 100 ng/ml
rWnt5a was used for the remaining studies hereafter to
Figure 1 Effect of Wnt5a on the migration of osteosarcoma cells. Relative cell migration rate was determined by using wound healing assay
(A) and Boyden chamber assays (B) in MG-63 cells incubated in the absence (0 ng/ml) or presence of 50, 100, and 200 ng/ml Wnt5a for 10 h.
*, **: p < 0.05, p < 0.01 in the cultures with Wnt5a relative to the cultures without Wnt5a, respectively. Data were presented as mean ± SD of
5 determinations.
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the migration of MG-63 cells.
Wnt5a induces PI3K and Akt phosphorylations
Wnt5a-triggered signals in human osteosarcoma cells
have remained completely unknown. To address the ques-
tion, we first tried to identify the downstream signals trig-
gered by Wnt5a in MG-63 cells. We first detected theFigure 2 Wnt5a induces PI3K activation of osteosarcoma cells. (A) Hu
or treated with 100 ng/ml of Wnt5a and harvested at 15 min, 30 min, and 1 h
antibodies to p-PI3K p85 (p-Tyr458) and total PI3K p85. p-PI3K/total PI3K ratios
determinations. *, **: p < 0.05, p < 0.01 in the cultures with Wnt5a relative to t
pre-treated with 20 μM LY294002 for 1 h. Relative cell migration rate was det
absence or presence of 100 ng/ml Wnt5a for 10 h. ** p < 0.01 in the cultures
as mean ± SD of 5 determinations.phosphorylated-PI3K p85 (p-Tyr458), which represents
the PI3K activation state. Human osteosarcoma cells,
serum-starved for 24 h, were treated with 100 ng/ml of
rWnt5a. The cells were harvested at 15 min, 30 min and
1 h after the start of Wnt5a treatment, followed by SDS-
PAGE and immunoblot analyses. PI3K showed visible
signs of basal phosphorylation and elevated phosphory-
lation at 15 min after stimulation with rWnt5a andman osteosarcoma cells MG-63, serum-deprived for 24 h, were untreated
after the start of treatment for SDS-PAGE and immunoblot analysis with
were indicated at each time. Data were presented as mean ± SD of 3
he cultures without Wnt5a. (B) Serum-deprived MG-63 cells were
ermined by using wound healing assay in MG-63 cells incubated in the
with Wnt5a relative to the cultures without Wnt5a. Data were presented
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start of treatment with Wnt5a (Figure 2A).
The most established activator of Akt is PI3K, there-
fore we sought to determine whether Akt activation was
triggered by Wnt5a. The same assays were performed to
detect the phosphorylated-Akt (p-Ser473), which repre-
sents the Akt activation state. Akt also showed visible
signs of basal phosphorylation and elevated phospho-
rylation at 15 min after stimulation with rWnt5a and
continued to be elevated at least until 1 h after the start
of treatment with Wnt5a (Figure 3A).
Wnt5a promotes cell migration via PI3K pathway
The finding that Wnt5a could induce PI3K/Akt phos-
phorylation in MG-63 cells prompted us to determine
whether PI3K/Akt activation was required for Wnt5a-
mediated cell migration. Wnt5a-induced cell migration
was largely abolished by pre-treatment with 20 μM
LY294002, the PI3K-specific inhibitor (Figure 2B), sug-
gesting that PI3K activation is required for Wnt5a-
induced MG-63 cell migration.
To demonstrate the involvement of PI3K in Wnt5a-in-
duced activation of Akt, we tested the effect of LY294002
for Akt activation. Human osteosarcoma cells, serum-
starved for 24 h and pretreated with 20 μM LY294002 for
1 h, were incubated with 100 ng/ml of Wnt5a. The cells
were harvested 15 min after the start of Wnt5a treatment
and the cell lysates were subjected to SDS-PAGE and
immunoblot analysis. The Wnt5a-induced activation of
Akt was mostly blocked by pretreatment of LY294002
(Figure 3B). These data indicate that PI3K mediates
Wnt5a-induced activation of Akt.Figure 3 Wnt5a promotes cell migration via Akt pathway. (A) Human
treated with 100 ng/ml of Wnt5a and harvested at 15 min, 30 min, and 1 h a
antibodies to p-Akt (p-Ser473) and total Akt. p-Akt/total Akt ratios were indica
*, **: p < 0.05, p < 0.01 in the cultures with Wnt5a relative to the cultures with
20 μM LY294002 (PI3K inhibitor) for 1 h, then incubated with 100 ng/ml Wnt5
with p-Akt (p-Ser473) or total Akt antibodies. Data were presented as mean ±
Wnt5a relative to the cultures without Wnt5a.Akt activation regulates osteosarcoma cell migration
To analyze the role of endogenous Akt activation on
Wnt5a-induced cell migration, we knocked down Akt
expression by using siRNA, which reduced the protein
level of Akt by approximately 60%, as assessed by im-
munoblotting (Figure 4A) and significantly reduced
Wnt5a-induced migration of MG-63 cells (Figure 4B).
Taken together, these experiments demonstrated that
Akt activation was required for Wnt5a-induced MG-63
cell migration.
Wnt5a does not alter the total expression and
phosphorylation of β-catenin
Mikels and Nusse reported that purified Wnt5a inhibits
Wnt3a protein-induced canonical Wnt signaling in a
dose-dependent manner, not by influencing β-catenin
levels but by downregulating β-catenin-induced reporter
gene expression in HEK293 cells or mouse L cells [17].
To assess the effect of Wnt5a on the total expression
and phosphorylation of β-catenin, we treated MG-63
cells with different doses of rWnt5a, and measured the
total expression and phosphorylation by immunoblotting
assays. We found that the total expression and phos-
phorylation of β-catenin had not been altered under
Wnt5a stimulation for less than 1 hour (Figure 5).
Discussion
Wnt5a is a prototypic ligand that activates a β-catenin
independent pathway in Wnt signaling [3]. Mice with
the disrupted Wnt5a gene also exhibit various develop-
mental abnormalities such as dwarfism, facial abnor-
malities, shortened limbs and tails, dysmorphic ribs andosteosarcoma cells MG-63, serum-deprived for 24 h, were untreated or
fter the start of treatment for SDS-PAGE and immunoblot analysis with
ted at each time. Data were presented as mean ± SD of 3 determinations.
out Wnt5a. (B) An equal number of MG-63 cells were pre-treated with
a for 15 min. After stimulation, cells were analyzed by immunoblotted
SD of 3 determinations. **, ##: p < 0.01, p < 0.01, in the cultures with
Figure 4 Effect of Akt in Wnt5a-induced cell migration. (A) Effect of Akt siRNA on the expression of Akt. MG-63 cells were transiently transfected
with Akt siRNA pool, or mock for 48 h. Cells were analyzed by immunoblotted with total Akt antibody. (B) Effect of Akt siRNA on Wnt5a-stimulated cell
migration. Cells were transiently transfected with Akt siRNA pool, and stimulated with 100 ng/ml Wnt5a or not for 10 h. Relative cell migration rate
was determined by using wound healing assay. ** p < 0.01 in the cultures with Wnt5a relative to the cultures without Wnt5a. Data were presented as
mean ± SD of 5 determinations.
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distal lung morphogenesis, indicating that it plays a cru-
cial role in the development of various organs [18].
Wnt5a has been demonstrated to exert differential ef-
fects on cancer development [5]. Wnt5a can promote
cancer progression and metastasis in malignant mela-
noma, breast cancer, and gastric cancer [19-23]. How-
ever, some evidence supports the hypothesis that Wnt5a
acts as a tumor suppressor in certain experimental sys-
tems [24-28]. The first observation in the present study
was that Wnt5a induced the migration of MG-63 osteo-
sarcoma cells. Our finding suggest that Wnt5a acts as a
migratory stimulator in osteosarcoma cells.
Kinases show the comprehensive functions triggered
by Wnt5a in a variety of cells. It has been reported that
Wnt5a may promote tumor progression through indu-
cing actin reorganization and increasing cell motility via
activating the protein kinase C (PKC) [19,29]. Wnt5a ac-
tivates extracellular regulated protein kinase (ERK) in
endothelial cells [30]. Wnt5a prevents apoptosis caused
by serum-deprivation in osteoblasts by activating bothFigure 5 Wnt5a does not alter the total expression and
phosphorylation of β-catenin. MG-63 were untreated or treated
with 100 ng/ml of Wnt5a and harvested at 15 min, 30 min, and 1 h
after the start of treatment for SDS-PAGE and immunoblot analysis
with antibodies to p-β-catenin (p-Ser33) and total β-catenin. The
total expression and phosphorylation of β-catenin were not been
altered by Wnt5a stimulation.Akt and ERK [12], and promotes cell adhesion in mam-
mary epithelial cells in a PI3K/Akt-dependent manner
[31]. Furthermore, Wnt5a triggers Akt phosphorylation
via PI3K, but not ERK or PKC phosphorylation in human
dermal fibroblasts [14]. These tanglesome viewpoints of
kinases in Wnt5a signaling indicate that phosphorylated
signaling molecules triggered by Wnt5a in these cases de-
termine the diverse roles of these kinases. In this study,
we demonstrated that Wnt5a promoted MG-63 osteosar-
coma cell migration by activating PI3K/Akt. We found
that Wnt5a induced PI3K (p-Tyr458) and Akt phosphory-
lation (p-Ser473) rapidly and transiently in MG-63 cells.
Blocking Akt signaling by chemical inhibition of PI3K or
Akt siRNA completely abolished Wnt5a-induced cell
migration, indicating that PI3K/Akt activation participated
in the regulation of the MG-63 cell migration.
The activation of PI3K/Akt signaling is thought to play
a central role in cell viability-promoting phenotypes such
as inhibition of cell death and cell cycle progression [14].
It has been shown that the PI3K/Akt signaling could be
activated not only by Wnt5a but also by Wnt3a. Wnt3a
prevents the serum deprivation-triggered apoptosis of
osteoblasts by activating the canonical β-catenin pathway,
ERK-, and/or PI3K-mediated uncharacterized pathways
[12]. In this study, we have showed that Wnt5a pro-
motes cell migration of human osteosarcoma cells in the
PI3K/Akt-dependent manner. These results indicated that
PI3K/Akt played crucial and complicated roles in cano-
nical and non-canonical Wnt signalings in various cell
and tissue types. Besides mentions above, PI3K/Akt sig-
naling presents wide crosstalks referred to instances in
which one or more components of one signal trans-
duction pathway affect another. High-mobility group box
1 (HMGB1) activates the FAK/PI3K/mTOR signaling
cascade and regulates tumor-associated cell migration
through the interaction with BTB domain [32]. CXCR4
drives the metastatic phenotype in breast cancer through
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pathways [33]. Akt signaling is involved in fucoidan-
induced inhibition of growth and migration of human
bladder cancer cells [34]. These studies provide us a
complicated and crossed network around the PI3K/Akt
signaling.
In summary, we present the first direct evidence here
that Wnt5a promotes osteosarcoma cell migration via
PI3K/Akt signaling. These findings elucidate a molecular
pathway linking Wnt5a signaling to PI3K/Akt in cell
motility. This result will contribute to further under-
standing of biological roles of Wnt5a/PI3K/Akt in cell
migration of osteosarcoma and other cancers.
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